US pharmaceutical company Eli Lilly and Company (NYSE:LLY) announced on Wednesday that it has received approval from the US Food and Drug Administration (FDA) for Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults.
Omvoh is now approved in the United States for two types of inflammatory bowel disease (IBD), following its October 2023 approval as a first-in-class treatment for moderately to severely active ulcerative colitis (UC) in adults. Omvoh works to reduce inflammation within the gastrointestinal tract by targeting a specific protein, interleukin-23p19 (IL-23p19), which is a key contributor to intestinal inflammation. Lilly says that Omvoh is the first biologic treatment in more than 15 years to have disclosed two-year Phase 3 efficacy data in Crohn's disease at the time of approval.
The FDA decision was based on positive results from the Phase 3 VIVID-1 study of Omvoh in adults with moderately to severely active Crohn's disease who had an inadequate response, loss of response, or intolerance to corticosteroids, immunomodulators (azathioprine, 6-mercaptopurine and methotrexate) and/or biologics (TNF blockers, integrin receptor antagonists).
Pharming receives UK NICE recommendation for Joenja to treat APDS in patients aged 12 and older
Tagworks Pharmaceuticals' TGW101 IND application granted FDA clearance for Phase 1 clinical trial
Kelun-Biotech's SKB518 granted IND clearance by US FDA
Renalytix reports real-world impact of KidneyIntelX on targeted kidney disease treatment
Intas and Accord BioPharma complete acquisition of UDENYCA (pegfilgrastim-cbqv) business
IDEAYA Biosciences advances Phase 3 design for darovasertib in primary uveal melanoma
Halozyme Therapeutics' VYVGART Hytrulo prefilled syringe for self-injection receives US FDA approval